Recent studies have highlighted the potential of Wegovy, a popular weight-loss medication produced by Novo Nordisk, in treating heart failure symptoms beyond its known benefits for weight loss. The drug has shown promise in easing heart failure symptoms for patients with diabetes, suggesting its utility in addressing health conditions related to obesity. This development is based on positive trial results and a new study indicating that Wegovy's heart benefits are not solely linked to weight loss. Researchers, including those from @MkosiborodMD @midamericaheart @saintlukeskc, note that while weight loss may play a role in the drug's benefits for heart-failure patients, it is not the complete explanation. A pooled analysis of two Wegovy HFpEF trials revealed that patients with more severe heart failure experienced greater symptom benefits, despite similar weight loss to others, supporting the idea that Wegovy aids heart health in ways beyond mere weight reduction. The findings, confirmed by NEJM and reported by @statnews, set the stage for broader use of the drug.
Pooled analysis of the two Wegovy HFpEF trials finds that patients with more severe heart failure saw greater symptom benefits, even though their weight loss was similar to others Supports idea that Wegovy helps the heart in ways beyond just weight loss https://t.co/nG3z8dmeW8
$LLY $NVO $VKTX The War on Obesity, and Heart disease? Perhaps it stands to reason that, for heart failure related to obesity, Wegovy, a Tx that reduces obesity, would have a statistically significant beneficial effect. However, still good to have NEJM confirmation. And… https://t.co/uhUN9xGWFw https://t.co/wJl0DRQX4q
The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to a new study. https://t.co/AxMIIt3WOF
While weight loss may be an important factor behind Wegovy's benefits for heart-failure patients, it's not the whole story, new research shows. @MkosiborodMD @midamericaheart @saintlukeskc https://t.co/7IcCa9I63F
Wegovy, the blockbuster weight-loss medication from Novo Nordisk, eased heart failure symptoms for patients with diabetes in the latest large trial to support use of the drug to treat health conditions linked to obesity https://t.co/96fdqb0n1U
A new study shows the obesity drug Wegovy improved function in patients with a common type of heart failure and diabetes, setting the stage for even broader use of the… https://t.co/8iObfdr6XJ
BREAKING: Positive trial results set up obesity drug Wegovy for use against heart failure https://t.co/huMryxxC4u via @statnews @elaineywchen #ACC24 @ACCinTouch
Wegovy’s heart benefits are not just linked with weight loss, new study suggests https://t.co/qWPfc8LBvZ